Wide mismatches in the sequences of primers and probes for Monkeypox virus diagnostic assays

Data source

The MPV genomes were downloaded from GISAID (https://gisaid.org/). As of August 5, 2022, 683 genomes with complete metadata were available, including 634 genomes (samples) collected from May 19, 2022, to July 29, 2022. The rest 49 samples include 7 from 1962 to 2005, 11 samples in 2006, 12 samples in 2007, 7 samples in 2017, 8 samples in 2018, 2 samples in 2019, and 2 samples in 2021. Metadata includes accession ID, sample collection date, sequence data submission date, and sampling location (Continent/country) associated with the sequences. The monkeypox virus reference genome Zaire-96-I-16 was downloaded from NCBI (NC_003310.1). MPV real-time assays (primers and probes) were from published studies including MPV Generic assay (9), MPV_O2L (13), MPV_F3L (14), MPV_C3L (10), MPV_G2R_WA (10), OPV_B2R (15), OPV_I7L (16), and OPV_F8L (17).

Sequence alignment

Genome sequences were downloaded as .fasta and imported into R (version 4.1.3) as the MPV genome database for analysis. We aligned each of the oligo (including forward primer, reverse primer, and probe) sequence to the database and computed the percentage of matches and non-matches. For non-matches, sequence was extracted and aligned by SnapGene software (https://www.snapgene.com/) to identify the specific nucleotides that are distinct from sequence in the MPV oligos. If the ‘mismatch’ in the targeted genome region is the correct degenerate codes, we treated it as ‘match’. If the ‘mismatch’ is ‘N’ or multiple ‘N’, we treated as ‘non-match’. The major types of sequence variation (mutation) were listed in Figure 1 and Figure 3A. In total, the original sequence and identified sequence variation account for 99.4% ∼ 100% of the total genomes for each of the MPV real-time assays. Four genomes (0.6%) were excluded in the MPV_F3L assay (forward primer) because non-match was found in the genome. These analyses were performed with customized R script.

• Download figure
• Open in new tab

Figure 1. MPV generic forward and reverse primers do not match with the majority of reported genomes.

(A) Alignment of MPV generic forward primer, reverse primer, and probe sequences (recommended in the CDC test procedure for MPV (9)) to the MPV reference genome (MPV-Zaire-96-I-16). The corresponding oligo sequences with mismatches found in the genome database for forward (MPV-F-mu) and reverse primers (MPV-R-mu) were also added on top of the reference genome. Red nucleotides indicate the variations identified in the 683 genome database and the nonsynonymous mutation is marketed by a red box. (B-C) The abundance of MPV-F (generic) and MPV-F-mu (mutated), MPV-R (generic) and mutated (MPV-R-mu) in the currently available 683 MPV genomes worldwide (B), and in the 58 U.S. genomes (C).

Mutation-based epidemiological analysis

For each MPV assay, we identified the major variation type(s) in the genome database and then assigned an identity as ‘match’ or ‘mutation’ to each of the genome for the specific oligo. Two mutation types were found for the MPV_G2R_WA assay and were labeled as ‘Mutation1’ and ‘Mutation2’, respectively. Merging with the metadata associated with the genome, we summarized the number of genomes for ‘match’ and ‘mutation’ groups based on the sampling collection time (year), sampling location (continent). We also sub-grouped the database by only selecting the year ‘2022’ to compute the percentages of ‘mutation’ in the current MPV outbreak.

Generic MPV forward and reverse primers do not match the majority of reported genomes

We investigated whether forward and reverse primers and probe in the MPV generic assay match to the reported MPV genomes. As of August 5, 683 complete genomes with metadata have been uploaded in the GISAID. Of the 683 genomes, 634 (92.8%) were collected between May 19 and July 29, 2022. We then aligned each of the MPV generic oligo sequences to the genome database. Of the total 683 genomes, the MPV generic forward sequence (MPV-F, Figure 1A) had 100% identity to sequences present in 28 (4%) of the genomes. A single-nucleotide mutation A194165G (synonymous mutation, MPV-F-mu in Figure 1A) was found in 96% of the published MPV genomes (Figure 1B), and 100% in the genomes published from May to July 2022. Similar observations were also found in the generic reverse primer (MPV-R), which only matches 8% of the genomes. A nonsynonymous substitution, C194233T in the reverse primer region, was observed in 92% of the genomes (equivalent to 98.4% of genomes released from May to July 2022). In contrast, the probe sequence (MPV-P) is conserved and matches all of the genomes in the database.

We further compared the MPV generic primers and probe with the sequenced samples in the U.S. Of the total 58 genomes, the A194165G mutation in the forward primer region was observed in all the U.S. genomes, and the C194233T mutation observed in the reverse primer region was found in 93% of the U.S. genomes (Figure 1C), which are consistent with the results in Figure 1B. These results demonstrated that the CDC recommended forward and reverse primers designed for MPV testing do not match the major genome sequences in recent samples with MPV.

Evaluation of the specificity of other primers and probes for monkeypox virus and orthopoxvirus detection

Next, we evaluated seven other developed real-time PCR assays, targeting O2L (13), F3L (14), C3L, and G2R (10) genes for MPV, B2R (15), I7L (16) and F8L (17) genes for OPV detection. The selected targets are generally conserved regions within viral genomes to maximize viral detection (13,15). We aligned primer and probe sequences used in each of the seven assays against the 683 MPV genomes and computed percent identity. As shown in Table 1, the four reported assays designed for MPV detection have varied results. The primers in MPV_O2L have a >99% match with the database, but the probe only matches 4.1% of the genomes. A perfect match was not found for the MPV_C3L assay, which was used for the detection of the MPV Congo Basin strain. Primers and probe sequences used in the MPV_F3L assay showed >99.4% alignment against the genome database, suggesting its suitability for detection of the MPV-2022 outbreak. Primers used in the MPV_G2R assay designed to detect the West African strain showed a 100% match to the database and 95.6% match for the probe thereby validating previous phylogenetic analysis results that the current MPV lineage belongs to the West Africa clade (20).

We further evaluated three real-time assays (OPV_B2R, OPV_I7L, and OPV_F8L) for the detection of viruses belonging to the genus orthopoxvirus, which includes monkeypox virus, camelpox virus, cowpox virus, and vaccinia virus (21). OPV_B2R primers highly match the database genomes, but its probe sequence has no match (Table 1). OPV_I7L has good matches for the forward primer and probe, but its reverse primer only matches 8.2% of the genomes. OPV_F8L oligos for the non-variola OPV generic test recommended by CDC has a high match percentage (>99.6%) with the genomes (Table 1). Thus, the MPV_F3L and OPV_F8L assays have the highest match rates to the sequenced MPV genomes.

Genetic variations across real-time PCR assays for MPV or OPV detection and epidemiological analysis

We next investigated genomic sequences in conserved regions that differ between the real-time PCR assays. About 96% of genomes have a G->T mutation in the probe of MPV_O2L assay, and this mutation is present across all MPV-2022 outbreak genomes (Figure 2A). Further analysis using the sample collection date found that this G->T mutation appeared in two samples in 1962 and 1970, was not detected in samples from 1978 to 2007, and re-emerged from 2017 onward (Figure 2B). For the OPV_I7L assay reverse primer, a C->T mutation was observed at the 3’ end in about 92% of all genomes and in 98.7% of genomes sequenced in 2022. It is interesting that this mutation is mostly observed in samples from Europe, South, and North America whereas the original sequence was more common in samples from Africa and Asia (Figure 2C). A G->C substitution in the probe sequence of OPV_B2R was observed in nearly all genomes sequenced in the MPV-2022 outbreak (Figure 2A).

• Download figure
• Open in new tab

Figure 2. Genetic variations across real-time PCR assays for MPV or OPV detection and epidemiological analysis.

(A) Genetic variations in the MPV genome database compared to primer and probe sequences used in detection assays. (B) Temporal analysis for the mutation in MPV_O2L probe sequence. This mutation is found in all the genomes in 2022. (C) Proportions of genomes for the reverse primer used in the OPV_I7L assay with or without mutation. (D) MPV_G2R_WA probe sequence and its two mutation types across the genomic database. One Mutation1 sample (green dot) was found in 2022 (overshadowed by the blue dot-Mutation2).

The MPV_G2R_WA assay probe has a 95.6% match to the database sequences (Figure 2A). Two mutation types were found for the rest of 4.3% genomes. A 7-nucleotide mutation (Mutation1) was found in 4.1% of genomes from 1978 to 2007 (Figure 2A and 2D). Mutation1 reappears in a sample obtained on June 10, 2022, from Luxembourg. Although 99.7% of the MPV genomes are conserved in this probe region, one new C->T synonymous mutation (Mutation2) (Figure 2A) was identified from a sample obtained on May 18, 2022 from Canada. Those results suggest that the genetic variations on the MPV genomes corresponding with the real-time PCR primer and probe regions could be used to indicate the temporal and spatial emergence pattern of monkeypox disease.